HighGravityDataCurrent guidance
4 items
Medtronic
Guidance from Medtronic’s last 8 earnings releases. Every value links to its sentence in the filing. See something wrong? Tell us.
Releases tracked
8
Latest release
Sep 1, 2026
Data checked
Sep 1, 2026
What changed in the Sep 1, 2026 release
Each item compared with the same item in the previous release (Jun 3, 2026). Values in quotation marks are the company’s words.
New — first stated in this releaseRaised / Lowered / Narrowed / Widened — changed from the prior releaseRevised — wording changed, direction not determinableChanged — value changed; the comparison couldn’t be parsed to a directionReiterated — restated unchangedNot restated — stated before, absent nowRaised and lowered describe the number, not whether the change is favorable.
| Change | Metric | Period | Previous | Now | Source |
|---|---|---|---|---|---|
| Raised | FY27 organic revenue growth | for FY2027 | “6.75% to 7.25%” | “7.25% to 7.75%” | Filing ↗ |
| Narrowed | FY27 diluted non-GAAP EPS | for FY2027 | “$5.90 to $6.00” | “$5.94 to $6.00” | Filing ↗ |
| New | Foreign currency exchange impact included in FY27 | for FY2027 | — | “neutral to 1% accretive” | Filing ↗ |
Show 1 item not restated in this release
| Change | Metric | Period | Previous | Now | Source |
|---|---|---|---|---|---|
| Not restated | Long-term organic revenue growth commitment | for the long term | “mid-single digit” | — | Filing ↗ |
Current guidance
Guidance for periods that have not yet ended, at its most recent value, grouped by horizon.
Current fiscal year
| Metric | Current value | Period | Measure | First stated | Times stated | Source |
|---|---|---|---|---|---|---|
| FY27 organic revenue growth | “7.25% to 7.75%” | for FY2027 | Company-defined | Jun 3, 2026 | 2 | Filing ↗ |
| FY27 diluted non-GAAP EPS | “$5.94 to $6.00” | for FY2027 | Company-defined | Jun 3, 2026 | 2 | Filing ↗ |
| Annual dividend | “$2.88 per share” | for FY2027 | Declared action | Jun 3, 2026 | 1 | Filing ↗ |
| Foreign currency exchange impact included in FY27 | “neutral to 1% accretive” | for FY2027 | Company-defined | Sep 1, 2026 | 1 | Filing ↗ |
Long term
| Metric | Current value | Period | Measure | First stated | Times stated | Source |
|---|---|---|---|---|---|---|
| Long-term organic revenue growth commitment | “mid-single digit” | for the long term | Company-defined | Nov 19, 2024 | 1 | Filing ↗ |
How one item moved
FY27 organic revenue growth, for FY2027 — every statement across the year, each linked to its filing.
How your Medical devices & equipment sector group guides
12 companies in Medical devices & equipment. What they guide on, and who reported this season.
Most-guided metric families
This season’s releases
| Medtronic | Sep 1, 2026 | 3 changes |
| Becton Dickinson | Aug 6, 2026 | 4 changes |
| ResMed | Aug 6, 2026 | 0 changes |
| Insulet | Aug 5, 2026 | 25 changes |
| Zimmer Biomet | Aug 5, 2026 | 3 changes |
| DexCom | Jul 30, 2026 | 3 changes |
| Stryker | Jul 30, 2026 | 2 changes |
| Boston Scientific | Jul 29, 2026 | 5 changes |
Get this for your own peer set — Peer Guidance Briefing, $3,000.
Full history
Every metric, every release, eight quarters — the complete record as one table.
| Metric | FY2027 | FY2026 | FY2025 | Long-term |
|---|---|---|---|---|
| FY25 revenue growth (including Other revenue and FX impact, if recent rates hold) | — | — | 2 statements | — |
| FY26 revenue growth on a reported basis (including Other revenue and FX impact) | — | 2 statements | — | — |
| FY27 organic revenue growth | 2 statements | 4 statements | 2 statements | — |
| Long-term organic revenue growth commitment | — | — | — | 1 statement |
| Adjusted EPS growth | — | — | 1 statement | — |
The full record for Medtronic and its Medical devices & equipment peers, delivered as a Peer Guidance Briefing — PDF and Excel, every value linked to its filing.
Filings
The 8 earnings releases this page is built from.
| Filed | Fiscal period | Accession | Guidance items | |
|---|---|---|---|---|
| Sep 1, 2026 | FY2027 Q1 | 0001628280-26-059697 | 3 | Open filing ↗ |
| Jun 3, 2026 | FY2026 Q4 | 0001628280-26-040034 | 6 | Open filing ↗ |
| Feb 17, 2026 | FY2026 Q3 | 0001628280-26-008300 | 4 | Open filing ↗ |
| Nov 18, 2025 | FY2026 Q2 | 0001628280-25-052771 | 4 | Open filing ↗ |
| Aug 18, 2025 | FY2026 Q1 | 0001613103-25-000141 | 4 | Open filing ↗ |
| May 21, 2025 | FY2025 Q4 | 0001613103-25-000078 | 5 | Open filing ↗ |
| Feb 18, 2025 | FY2025 Q3 | 0001613103-25-000019 | 5 | Open filing ↗ |
| Nov 19, 2024 | FY2025 Q2 | 0001613103-24-000162 | 6 | Open filing ↗ |
Not located in filing
2 values were detected in these releases but could not be matched to an exact sentence in the filing body, so they are not shown as guidance. We surface the count rather than drop it silently.
Show the 2 unmatched spans
| Span | Why | Filed |
|---|---|---|
| FY26 potential tariff impact = approximately $185 million | span gate: value not verbatim in filing | Aug 18, 2025 |
| Potential impact from tariffs = approximately $185 million | span gate: value not verbatim in filing | Aug 18, 2025 |
Values in quotation marks are the company’s words; the classification and filing links are HighGravityData’s. HighGravityData does not score or rank companies or give investment advice.
Report an error